1	Therapeutic	Therapeutic	B-NP	JJ	O	3	NMOD	-1
2	Electromagnetic	Electromagnetic	I-NP	JJ	O	3	NMOD	-1
3	Field	Field	I-NP	NN	O	9	NMOD	-1
4	(	(	O	(	O	6	DEP	-1
5	TEMF	TEMF	B-NP	NN	B-protein	6	DEP	-1
6	)	)	O	)	O	3	NMOD	-1
7	and	and	O	CC	O	9	NMOD	-1
8	gamma	gamma	B-NP	NN	O	9	NMOD	-1
9	irradiation	irradiation	I-NP	NN	O	0	ROOT	-1
10	on	on	B-PP	IN	O	9	NMOD	-1
11	human	human	B-NP	JJ	O	15	NMOD	-1
12	breast	breast	I-NP	NN	O	15	NMOD	-1
13	cancer	cancer	I-NP	NN	O	15	NMOD	-1
14	xenograft	xenograft	I-NP	NN	O	15	NMOD	-1
15	growth	growth	I-NP	NN	O	19	NMOD	4	growth
16	,	,	O	,	O	19	P	-1
17	angiogenesis	angiogenesis	B-NP	NN	O	19	NMOD	3	angiogenesis
18	and	and	I-NP	CC	O	19	NMOD	-1
19	metastasis	metastasis	I-NP	NN	O	10	PMOD	0
20	.	.	O	.	O	9	P	-1

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	The	The	B-NP	DT	O	4	NMOD	-1
4	effects	effect	I-NP	NNS	O	1	OBJ	0
5	of	of	B-PP	IN	O	4	NMOD	-1
6	a	a	B-NP	DT	O	9	NMOD	-1
7	rectified	rectify	I-NP	VBN	O	9	NMOD	-1
8	semi-sinewave	semi-sinewave	I-NP	NN	O	9	NMOD	-1
9	signal	signal	I-NP	NN	O	5	PMOD	-1
10	(	(	O	(	O	9	NMOD	-1
11	15	15	B-NP	CD	O	13	NMOD	-1
12	mT	mT	I-NP	NN	O	13	NMOD	-1
13	amplitude	amplitude	I-NP	NN	O	16	NMOD	-1
14	,	,	O	,	O	16	P	-1
15	120	120	B-NP	CD	O	16	NMOD	-1
16	pulses	pulse	I-NP	NNS	O	50	SUB	-1
17	per	per	B-PP	IN	O	16	NMOD	-1
18	second	second	B-NP	NN	O	17	PMOD	-1
19	,	,	O	,	O	50	P	-1
20	EMF	EMF	B-NP	NNP	O	21	NMOD	-1
21	Therapeutics	Therapeutics	I-NP	NNP	O	23	NMOD	-1
22	,	,	I-NP	,	O	23	P	-1
23	Inc.	Inc.	I-NP	NNP	O	50	VMOD	-1
24	)	)	O	)	O	23	NMOD	-1
25	(	(	O	(	O	27	DEP	-1
26	TEMF	TEMF	B-NP	NN	O	27	DEP	-1
27	)	)	O	)	O	23	NMOD	-1
28	alone	alone	B-ADVP	RB	O	23	NMOD	-1
29	and	and	O	CC	O	50	VMOD	-1
30	in	in	B-PP	IN	O	50	VMOD	-1
31	combination	combination	B-NP	NN	O	30	PMOD	-1
32	with	with	B-PP	IN	O	31	NMOD	-1
33	gamma	gamma	B-NP	SYM	O	34	NMOD	-1
34	irradiation	irradiation	I-NP	NN	O	38	NMOD	-1
35	(	(	O	(	O	37	DEP	-1
36	IR	IR	B-NP	NN	O	37	DEP	-1
37	)	)	O	)	O	34	NMOD	-1
38	therapy	therapy	B-NP	NN	O	32	PMOD	0
39	in	in	B-PP	IN	O	38	NMOD	-1
40	nude	nude	B-NP	JJ	O	41	NMOD	-1
41	mice	mouse	I-NP	NNS	O	39	PMOD	-1
42	bearing	bear	B-VP	VBG	O	41	NMOD	-1
43	a	a	B-NP	DT	O	49	NMOD	-1
44	human	human	I-NP	JJ	O	49	NMOD	-1
45	MDA	MDA	I-NP	NN	O	49	NMOD	-1
46	MB231	MB231	I-NP	NN	O	49	NMOD	-1
47	breast	breast	I-NP	NN	O	49	NMOD	-1
48	cancer	cancer	I-NP	NN	O	49	NMOD	-1
49	xenograft	xenograft	I-NP	NN	O	42	OBJ	-1
50	were	be	B-VP	VBD	O	10	SBAR	-1
51	tested	test	I-VP	VBN	O	50	VC	-1
52	.	.	O	.	O	1	P	-1

1	Green	Green	B-NP	JJ	B-cell_type	3	NMOD	-1
2	fluorescence	fluorescence	I-NP	NN	I-cell_type	3	NMOD	-1
3	protein	protein	I-NP	NN	I-cell_type	6	NMOD	-1
4	transfected	transfecte	B-VP	VBN	I-cell_type	6	NMOD	19	transfected
5	cancer	cancer	B-NP	NN	I-cell_type	6	NMOD	-1
6	cells	cell	I-NP	NNS	I-cell_type	7	SUB	-1
7	were	be	B-VP	VBD	O	0	ROOT	-1
8	injected	inject	I-VP	VBN	O	7	VC	19	injected
9	into	into	B-PP	IN	O	8	VMOD	-1
10	the	the	B-NP	DT	O	13	NMOD	-1
11	mammary	mammary	I-NP	JJ	O	13	NMOD	-1
12	fat	fat	I-NP	JJ	O	13	NMOD	-1
13	pad	pad	I-NP	NN	O	9	PMOD	-1
14	of	of	B-PP	IN	O	13	NMOD	-1
15	young	young	B-NP	JJ	O	17	NMOD	-1
16	female	female	I-NP	JJ	O	17	NMOD	-1
17	mice	mouse	I-NP	NNS	O	14	PMOD	-1
18	.	.	O	.	O	7	P	-1

1	Six	Six	B-NP	CD	O	2	NMOD	-1
2	weeks	week	I-NP	NNS	O	6	SUB	-1
3	later	later	B-ADVP	RB	O	6	VMOD	-1
4	,	,	O	,	O	6	P	-1
5	mice	mouse	B-NP	NNS	O	6	SUB	-1
6	were	be	B-VP	VBD	O	0	ROOT	-1
7	randomly	randomly	I-VP	RB	O	6	VMOD	-1
8	divided	divide	I-VP	VBN	O	6	VC	-1
9	into	into	B-PP	IN	O	8	VMOD	-1
10	four	four	B-NP	CD	O	12	NMOD	-1
11	treatment	treatment	I-NP	NN	O	12	NMOD	0
12	groups	group	I-NP	NNS	O	9	PMOD	-1
13	:	:	O	:	O	6	P	-1
14	untreated	untreated	B-NP	JJ	O	15	NMOD	0
15	controls	control	I-NP	NNS	O	6	PRD	0
16	;	;	O	:	O	6	P	-1
17	10	10	B-NP	CD	O	20	NMOD	-1
18	minute	minute	I-NP	JJ	O	20	NMOD	-1
19	daily	daily	I-NP	JJ	O	20	NMOD	-1
20	TEMF	TEMF	I-NP	NN	O	23	NMOD	-1
21	;	;	O	:	O	23	P	-1
22	200	200	B-NP	CD	O	23	NMOD	-1
23	cGy	cGy	I-NP	NN	O	28	NMOD	-1
24	of	of	B-PP	IN	O	23	NMOD	-1
25	IR	IR	B-NP	NN	O	24	PMOD	-1
26	every	every	B-NP	DT	O	28	NMOD	-1
27	other	other	I-NP	JJ	O	28	NMOD	-1
28	day	day	I-NP	NN	O	38	NMOD	-1
29	(	(	O	(	O	33	DEP	-1
30	total	total	B-NP	NN	O	32	NMOD	-1
31	800	800	I-NP	CD	O	32	NMOD	-1
32	cGy	cGy	I-NP	NN	O	33	DEP	-1
33	)	)	O	)	O	28	NMOD	-1
34	;	;	O	:	O	38	P	-1
35	IR	IR	B-NP	NN	B-protein	38	NMOD	-1
36	plus	plus	O	CC	O	38	NMOD	-1
37	daily	daily	B-NP	JJ	O	38	NMOD	-1
38	TEMF	TEMF	I-NP	NN	O	6	VMOD	-1
39	.	.	O	.	O	6	P	-1

1	Some	Some	B-NP	DT	O	2	NMOD	-1
2	mice	mouse	I-NP	NNS	O	6	SUB	-1
3	in	in	B-PP	IN	O	2	NMOD	-1
4	each	each	B-NP	DT	O	5	NMOD	-1
5	group	group	I-NP	NN	O	3	PMOD	-1
6	were	be	B-VP	VBD	O	0	ROOT	-1
7	euthanized	euthanize	I-VP	VBN	O	6	VC	19	euthanized
8	24	24	B-NP	CD	O	9	NMOD	-1
9	hours	hour	I-NP	NNS	O	10	PMOD	-1
10	after	after	B-PP	IN	O	7	VMOD	-1
11	the	the	B-NP	DT	O	12	NMOD	-1
12	end	end	I-NP	NN	O	10	PMOD	-1
13	of	of	B-PP	IN	O	12	NMOD	-1
14	IR	IR	B-NP	NN	B-protein	13	PMOD	-1
15	.	.	O	.	O	6	P	-1

1	TEMF	TEMF	B-NP	NN	O	2	NMOD	-1
2	treatment	treatment	I-NP	NN	O	3	SUB	0
3	continued	continue	B-VP	VBD	O	0	ROOT	-1
4	for	for	B-PP	IN	O	3	VMOD	-1
5	3	3	B-NP	CD	O	7	NMOD	-1
6	additional	additional	I-NP	JJ	O	7	NMOD	-1
7	weeks	week	I-NP	NNS	O	4	PMOD	-1
8	.	.	O	.	O	3	P	-1

1	Tumor	Tumor	B-NP	NN	O	2	NMOD	-1
2	sections	section	I-NP	NNS	O	3	SUB	-1
3	were	be	B-VP	VBD	O	0	ROOT	-1
4	stained	stain	I-VP	VBN	O	3	VC	-1
5	for	for	B-PP	IN	O	4	VMOD	-1
6	:	:	O	:	O	5	P	-1
7	endothelial	endothelial	B-NP	JJ	B-cell_type	8	NMOD	-1
8	cells	cell	I-NP	NNS	I-cell_type	5	PMOD	-1
9	with	with	B-PP	IN	O	8	NMOD	-1
10	CD31	CD31	B-NP	NN	B-protein	17	NMOD	-1
11	and	and	O	CC	O	17	NMOD	-1
12	PAS	PAS	B-NP	NN	O	17	NMOD	-1
13	or	or	O	CC	O	17	NMOD	-1
14	hypoxia	hypoxia	B-NP	NN	O	17	NMOD	-1
15	inducible	inducible	I-NP	JJ	O	17	NMOD	0
16	factor	factor	I-NP	NN	O	17	NMOD	-1
17	1alpha	1alpha	I-NP	NN	O	9	PMOD	-1
18	(	(	O	(	O	20	DEP	-1
19	HIF	HIF	B-NP	NN	B-protein	20	DEP	-1
20	)	)	O	)	O	17	NMOD	-1
21	.	.	O	.	O	3	P	-1

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	-1
3	Most	Most	B-NP	JJS	O	4	NMOD	-1
4	tumors	tumor	I-NP	NNS	O	9	SUB	-1
5	less	less	B-NP	JJR	O	4	NMOD	-1
6	than	than	I-NP	IN	O	5	AMOD	-1
7	35	35	I-NP	CD	O	8	NMOD	-1
8	mm3	mm3	I-NP	NN	O	6	PMOD	-1
9	were	be	B-VP	VBD	O	17	VMOD	-1
10	white	white	B-ADJP	JJ	O	17	VMOD	-1
11	but	but	O	CC	O	17	VMOD	-1
12	tumors	tumor	B-NP	NNS	O	17	SUB	-1
13	greater	great	B-ADJP	JJR	O	12	NMOD	-1
14	than	than	B-PP	IN	O	13	AMOD	-1
15	35	35	B-NP	CD	O	16	NMOD	-1
16	mm3	mm3	I-NP	NN	O	14	PMOD	-1
17	were	be	B-VP	VBD	O	1	NMOD	-1
18	pink	pink	B-ADJP	JJ	O	17	PRD	-1
19	and	and	O	CC	O	17	VMOD	-1
20	had	have	B-VP	VBD	O	17	VMOD	-1
21	a	a	B-NP	DT	O	23	NMOD	-1
22	vascularized	vascularize	I-NP	VBN	O	23	NMOD	0
23	capsule	capsule	I-NP	NN	O	20	OBJ	-1
24	.	.	O	.	O	1	P	-1

1	The	The	B-NP	DT	O	2	NMOD	-1
2	cortex	cortex	I-NP	NN	O	9	SUB	-1
3	within	within	B-PP	IN	O	2	NMOD	-1
4	100	100	B-NP	CD	O	5	NMOD	-1
5	microns	micron	I-NP	NNS	O	3	PMOD	-1
6	of	of	B-PP	IN	O	5	NMOD	-1
7	the	the	B-NP	DT	O	8	NMOD	-1
8	capsule	capsule	I-NP	NN	O	6	PMOD	-1
9	had	have	B-VP	VBD	O	0	ROOT	-1
10	little	little	B-NP	JJ	O	11	NMOD	-1
11	vascularization	vascularization	I-NP	NN	O	9	OBJ	3	vascularization
12	.	.	O	.	O	9	P	-1

1	Blood	Blood	B-NP	NN	O	2	NMOD	-1
2	vessels	vessel	I-NP	NNS	O	9	SUB	-1
3	,	,	O	,	O	9	P	-1
4	capillaries	capillary	B-NP	NNS	O	9	SUB	-1
5	,	,	O	,	O	9	P	-1
6	and	and	O	CC	O	9	VMOD	-1
7	endothelial	endothelial	B-NP	JJ	O	8	NMOD	-1
8	pseudopods	pseudopod	I-NP	NNS	O	9	SUB	-1
9	were	be	B-VP	VBD	O	0	ROOT	-1
10	found	find	I-VP	VBN	O	9	VC	0
11	at	at	B-PP	IN	O	10	VMOD	-1
12	greater	great	B-NP	JJR	O	13	AMOD	-1
13	than	than	I-NP	IN	O	15	NMOD	-1
14	100	100	I-NP	CD	O	13	AMOD	-1
15	microns	micron	I-NP	NNS	O	11	PMOD	-1
16	from	from	B-PP	IN	O	15	NMOD	-1
17	the	the	B-NP	DT	O	18	NMOD	-1
18	capsule	capsule	I-NP	NN	O	16	PMOD	-1
19	(	(	O	(	O	21	DEP	-1
20	subcortex	subcortex	B-NP	NN	O	21	DEP	-1
21	)	)	O	)	O	18	NMOD	-1
22	.	.	O	.	O	9	P	-1

1	Tumors	Tumor	B-NP	NNS	O	15	SUB	-1
2	greater	great	B-ADJP	JJR	O	1	NMOD	-1
3	than	than	B-PP	IN	O	2	AMOD	-1
4	35	35	B-NP	CD	O	5	NMOD	-1
5	mm3	mm3	I-NP	NN	O	3	PMOD	-1
6	treated	treat	B-VP	VBN	O	5	NMOD	19	treated
7	with	with	B-PP	IN	O	6	VMOD	-1
8	IR	IR	B-NP	NN	B-protein	10	NMOD	-1
9	24	24	B-NP	CD	I-protein	10	NMOD	-1
10	hours	hour	I-NP	NNS	I-protein	7	PMOD	-1
11	previously	previously	B-ADVP	RB	O	15	VMOD	-1
12	or	or	O	CC	O	11	DEP	-1
13	with	with	B-PP	IN	O	11	AMOD	-1
14	TEMF	TEMF	B-NP	NN	B-protein	13	PMOD	-1
15	had	have	B-VP	VBD	O	0	ROOT	-1
16	decreased	decrease	I-VP	VBN	O	15	VC	18	decreased
17	blood	blood	B-NP	NN	O	18	NMOD	-1
18	vessels	vessel	I-NP	NNS	O	16	OBJ	-1
19	in	in	B-PP	IN	O	18	NMOD	-1
20	the	the	B-NP	DT	O	21	NMOD	-1
21	subcortex	subcortex	I-NP	NN	O	25	NMOD	-1
22	and	and	O	CC	O	25	NMOD	-1
23	more	more	B-NP	RBR	O	24	AMOD	-1
24	endothelial	endothelial	I-NP	JJ	O	25	NMOD	-1
25	pseudopods	pseudopod	I-NP	NNS	O	19	PMOD	-1
26	projecting	project	B-VP	VBG	O	25	NMOD	-1
27	into	into	B-PP	IN	O	26	VMOD	-1
28	hypoxic	hypoxic	B-NP	JJ	O	32	NMOD	-1
29	,	,	I-NP	,	O	32	P	-1
30	HIF	HIF	I-NP	NN	B-protein	32	NMOD	-1
31	positive	positive	I-NP	JJ	O	32	NMOD	0
32	areas	area	I-NP	NNS	O	27	PMOD	-1
33	than	than	B-PP	IN	O	18	NMOD	-1
34	tumors	tumor	B-NP	NNS	O	33	PMOD	-1
35	from	from	B-PP	IN	O	34	NMOD	-1
36	the	the	B-NP	DT	O	38	NMOD	-1
37	control	control	I-NP	NN	O	38	NMOD	0
38	group	group	I-NP	NN	O	35	PMOD	-1
39	.	.	O	.	O	15	P	-1

1	Mice	Mouse	B-NP	NNS	O	0	ROOT	-1
2	that	that	B-NP	WDT	O	1	NMOD	-1
3	received	receive	B-VP	VBD	O	8	VMOD	19	received
4	either	either	O	CC	O	8	VMOD	-1
5	IR	IR	B-NP	NN	B-protein	7	NMOD	-1
6	or	or	I-NP	CC	O	7	NMOD	-1
7	TEMF	TEMF	I-NP	NN	B-protein	8	SUB	-1
8	had	have	B-VP	VBD	O	2	SBAR	-1
9	significantly	significantly	B-NP	RB	O	10	AMOD	-1
10	fewer	few	I-NP	JJR	O	17	NMOD	-1
11	lung	lung	I-NP	NN	B-DNA	13	NMOD	-1
12	metastatic	metastatic	I-NP	JJ	I-DNA	13	NMOD	0
13	sites	site	I-NP	NNS	I-DNA	10	NMOD	-1
14	and	and	O	CC	O	17	NMOD	-1
15	slower	slow	B-NP	JJR	O	17	NMOD	-1
16	tumor	tumor	I-NP	NN	O	17	NMOD	-1
17	growth	growth	I-NP	NN	O	8	OBJ	4	growth
18	than	than	B-SBAR	IN	O	8	VMOD	-1
19	did	do	O	VBD	O	18	DEP	-1
20	untreated	untreated	B-NP	JJ	O	21	NMOD	19	untreated
21	mice	mouse	I-NP	NNS	O	19	SUB	-1
22	.	.	O	.	O	1	P	-1

1	No	No	B-NP	DT	O	4	NMOD	-1
2	harmful	harmful	I-NP	JJ	O	4	NMOD	-1
3	side	side	I-NP	NN	O	4	NMOD	-1
4	effects	effect	I-NP	NNS	O	5	SUB	0
5	were	be	B-VP	VBD	O	0	ROOT	-1
6	attributed	attribute	I-VP	VBN	O	5	VC	-1
7	to	to	B-PP	TO	O	6	VMOD	-1
8	TEMF	TEMF	B-NP	NN	B-protein	7	PMOD	-1
9	.	.	O	.	O	5	P	-1

1	CONCLUSION	CONCLUSION	B-NP	NN	O	8	NMOD	-1
2	:	:	O	:	O	1	P	-1
3	TEMF	TEMF	B-NP	NN	O	4	NMOD	-1
4	therapy	therapy	I-NP	NN	O	5	SUB	0
5	provided	provide	B-VP	VBD	O	8	NMOD	-1
6	a	a	B-NP	DT	O	8	NMOD	-1
7	safe	safe	I-NP	JJ	O	8	NMOD	-1
8	means	mean	I-NP	NNS	O	0	ROOT	-1
9	for	for	B-PP	IN	O	8	NMOD	-1
10	retarding	retard	B-VP	VBG	O	9	PMOD	18	retarding
11	tumor	tumor	B-NP	NN	O	12	NMOD	-1
12	vascularization	vascularization	I-NP	NN	O	16	NMOD	3	vascularization
13	,	,	O	,	O	16	P	-1
14	growth	growth	B-NP	NN	O	16	NMOD	4	growth
15	and	and	I-NP	CC	O	16	NMOD	-1
16	metastasis	metastasis	I-NP	NN	O	10	OBJ	14	metastasis
17	.	.	O	.	O	8	P	-1

